HRP20200521T1 - Kombinacijske terapije za liječenje kemorezistentnih rakova - Google Patents

Kombinacijske terapije za liječenje kemorezistentnih rakova Download PDF

Info

Publication number
HRP20200521T1
HRP20200521T1 HRP20200521TT HRP20200521T HRP20200521T1 HR P20200521 T1 HRP20200521 T1 HR P20200521T1 HR P20200521T T HRP20200521T T HR P20200521TT HR P20200521 T HRP20200521 T HR P20200521T HR P20200521 T1 HRP20200521 T1 HR P20200521T1
Authority
HR
Croatia
Prior art keywords
compound
hypomethylating agent
dna hypomethylating
use according
independently
Prior art date
Application number
HRP20200521TT
Other languages
English (en)
Inventor
Daniel P. Gold
Guillermo Garcia-Manero
Original Assignee
Mei Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma, Inc. filed Critical Mei Pharma, Inc.
Publication of HRP20200521T1 publication Critical patent/HRP20200521T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245Amino benzoic acid types, e.g. procaine, novocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (9)

1. DNA hipometilirajuće sredstvo i spoj formule (Id): [image] naznačeni time što R1 je skupina koja ima formulu: - (CR20R21)m-(CR22R23)n-(CR24R25)o-NR26R27; R2 je alkil, fluoroalkil, cijano, C2-C6alkenil, C2-C6 alkinil ili heteroalkil, izborno supstituiran sa = 0; svaki R20, R21, R22, R23, R24 i R25 je samostalno H ili metil; svaki R26 i R27 je samostalno H, hidroksilalkil ili alkil; i m, n i o su samostalno cijeli brojevi od 0, 1, 2, 3 ili 4; ili farmaceutski prihvatljiva sol; za uporabu u liječenju kemorezistentnog karcinoma odabranog između mijelodisplastičnog sindroma (MDS) ili akutne mijeloidne leukemije (AML).
2. DNA hipometilirajuće sredstvo i spoj za uporabu prema zahtjevu 1, naznačeni time što su R26 i R27 samostalno H ili alkil.
3. DNA hipometilirajuće sredstvo i spoj za uporabu prema zahtjevu 2, naznačeni time što su R26 i R27 samostalno H, metil, etoil, izopropil, propil, butil, izobutil, heksil i heptil.
4. DNA hipometilirajuće sredstvo i spoj za uporabu prema zahtjevima 1 do 3, naznačeni time što R1 je CH2CH2N(CH2CH3)2.
5. DNA hipometilirajuće sredstvo i spoj za uporabu prema zahtjevu 1 ili 2, naznačeni time što R2 je butil.
6. DNA hipometilirajuće sredstvo i spoj za uporabu prema bilo kojem od zahtjeva 1 ili 5, naznačeni time što je rak rezistentan na azacitidin, decitabin, lenalidomid, TXA-127 ili kombinacije istih.
7. DNA hipometilirajuće sredstvo i spoj za uporabu prema bilo kojem od zahtjeva 1-6, naznačeni time što spoj formule (Id) ima strukturu: [image]
8. DNA hipometilirajuće sredstvo i spoj za uporabu prema bilo kojem od zahtjeva 1-7, naznačeni time što je DNA hipometilirajuće sredstvo 5-azacitidin (azacitidin).
9. DNA hipometilirajuće sredstvo i spoj za uporabu prema bilo kojem od zahtjeva 1 do 7, naznačeni time što DNA hipometilirajuće sredstvo je 5-azacitidin (azacitidin), 5-azadeoksicitidin (decitabin), SGI-110, zebularin ili prokain.
HRP20200521TT 2012-10-30 2020-03-30 Kombinacijske terapije za liječenje kemorezistentnih rakova HRP20200521T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261720346P 2012-10-30 2012-10-30
PCT/US2013/067607 WO2014070948A1 (en) 2012-10-30 2013-10-30 Combination therapies
EP13851971.5A EP2914254B1 (en) 2012-10-30 2013-10-30 Combination therapies to treat chemoresistant cancers

Publications (1)

Publication Number Publication Date
HRP20200521T1 true HRP20200521T1 (hr) 2020-08-07

Family

ID=50628036

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200521TT HRP20200521T1 (hr) 2012-10-30 2020-03-30 Kombinacijske terapije za liječenje kemorezistentnih rakova

Country Status (15)

Country Link
US (2) US20150258068A1 (hr)
EP (2) EP3662911A1 (hr)
JP (1) JP6343285B2 (hr)
CA (1) CA2927565C (hr)
CY (1) CY1123043T1 (hr)
DK (1) DK2914254T3 (hr)
ES (1) ES2774296T3 (hr)
HR (1) HRP20200521T1 (hr)
HU (1) HUE048584T2 (hr)
LT (1) LT2914254T (hr)
PL (1) PL2914254T3 (hr)
PT (1) PT2914254T (hr)
RS (1) RS60122B1 (hr)
SI (1) SI2914254T1 (hr)
WO (1) WO2014070948A1 (hr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7781595B2 (en) 2003-09-22 2010-08-24 S*Bio Pte Ltd. Benzimidazole derivatives: preparation and pharmaceutical applications
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
AR108257A1 (es) 2016-05-02 2018-08-01 Mei Pharma Inc Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
CA3090652A1 (en) 2018-02-06 2019-08-15 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
CN113412115A (zh) * 2018-11-30 2021-09-17 梅制药公司 针对高危和极高危mds的联合疗法
JP7115401B2 (ja) 2019-04-10 2022-08-09 株式会社デンソー モータ

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US20100098691A1 (en) * 2001-01-24 2010-04-22 S'bio Pte Ltd Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
WO2003012085A1 (en) * 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
JP2005517007A (ja) 2002-02-07 2005-06-09 アクシス・ファーマスーティカルズ ヒストンデアセチラーゼ阻害剤としての新規二環式ヒドロキサメート
US20040038304A1 (en) 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
TWI393708B (zh) * 2005-09-08 2013-04-21 Mei Pharma Inc 異羥肟酸脂化合物,其用途及其之合成方法
US7700567B2 (en) * 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
EP2331543A4 (en) * 2008-09-26 2013-06-19 Agency Science Tech & Res 3-DÉSAZANEPLANOCINE DERIVATIVES

Also Published As

Publication number Publication date
HUE048584T2 (hu) 2020-08-28
ES2774296T3 (es) 2020-07-20
EP2914254A1 (en) 2015-09-09
JP6343285B2 (ja) 2018-06-13
PL2914254T3 (pl) 2020-09-07
LT2914254T (lt) 2020-04-27
EP3662911A1 (en) 2020-06-10
PT2914254T (pt) 2020-04-02
DK2914254T3 (en) 2020-03-30
CA2927565C (en) 2021-05-18
JP2016501838A (ja) 2016-01-21
US20150258068A1 (en) 2015-09-17
US20210100775A1 (en) 2021-04-08
SI2914254T1 (sl) 2020-07-31
RS60122B1 (sr) 2020-05-29
CA2927565A1 (en) 2014-05-08
WO2014070948A1 (en) 2014-05-08
EP2914254B1 (en) 2020-01-08
CY1123043T1 (el) 2021-10-29
EP2914254A4 (en) 2016-06-29

Similar Documents

Publication Publication Date Title
HRP20200521T1 (hr) Kombinacijske terapije za liječenje kemorezistentnih rakova
HRP20210212T1 (hr) Triciklični spoj kao antikancerogeni agensi
JP2016500691A5 (hr)
NZ706985A (en) 2’-chloro nucleoside analogs for hcv infection
JP2016006118A5 (hr)
JP2016501838A5 (hr)
MX2021005087A (es) Compuestos de formula i para usarse en el tratamiento de infecciones por virus arenaviridae y coronaviridae.
WO2015081133A3 (en) Nucleotides for the treatment of liver cancer
PH12014502771A1 (en) Nucleoside phosphoramidate prodrugs
HRP20201023T1 (hr) Dioksilan analozi uridina za liječenje raka
JP2013507439A5 (hr)
BR112013012598A2 (pt) composição de oligossacarídeos para tratar infecções agudas do trato respiratório
CL2013003455A1 (es) Uso de compuestos inhibidores de sglt-2 derivados de benceno, sustituidos por glucopiranosilo para prevenir, desacelerar la progresion, retrasar o tratar un trastorno metabolico en un pacientes con un agente neuroleptico; uso de la combinacion del inhibidor de sglt2 con un neuroleptico; y composicion farmaceutica de la combinacion.
NZ613370A (en) Combinations for treating hcv
DK2528930T3 (da) 4'-azido-nukleosider som anti-hcv-forbindelser
EP2155771A4 (en) AZIDO PURINE NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS
JP2012092341A5 (hr)
JP2014507411A5 (hr)
JP2013507408A5 (hr)
JP2017061566A5 (hr)
JP2009536652A5 (hr)
ZA200704392B (en) Antibiotic combinations for providing total solution to the treatment of infections
AR090474A1 (es) Compuestos de tetrahidropirrolotiazina
AR097199A1 (es) Inhibidores de rorc2 y sus métodos de uso
WO2015031765A3 (en) Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections